Theseus Pharmaceuticals to Participate in the Cantor Future of Oncology Virtual Symposium

Rhea-AI Summary

Theseus Pharmaceuticals (NASDAQ: THRX) announced participation in the Cantor Future of Oncology Virtual Symposium from April 3-5, 2023. The company will present on April 3 at 2:00 PM ET. Theseus focuses on developing targeted therapies for cancer patients, including pan-variant tyrosine kinase inhibitors to combat resistant cancer mutations. Their lead candidate, THE-630, targets gastrointestinal stromal tumors, while THE-349 addresses resistance in non-small cell lung cancer. Live webcasts will be accessible to registered attendees of the symposium.

CAMBRIDGE, Mass., March 28, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) ("Theseus"), a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies, today announced that the company will participate in the Cantor Future of Oncology Virtual Symposium, taking place April 3-5, 2023.

Event: Cantor Future of Oncology Virtual Symposium
Panel Date / Time: Monday, April 3^rd at 2:00pm ET

A live webcast will be available for registered attendees and clients of Cantor.

About Theseus Pharmaceuticals, Inc.
Theseus is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development, and commercialization of transformative targeted therapies. Theseus is working to outsmart cancer resistance by developing pan-variant tyrosine kinase inhibitors (TKIs) to target all classes of cancer-causing and resistance mutations that lead to clinically relevant variants in a particular protein in a given type of cancer. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing THE-349, a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC), and a pan-variant BCR-ABL inhibitor for the treatment of relapsed/refractory chronic myeloid leukemia (CML) and newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). For more information, visit www.theseusrx.com.

Media Contact
Christen Baglaneas
Director, Corporate Communications & Investor Relations
Theseus Pharmaceuticals
857-706-4993
christen.baglaneas@theseusrx.com

Investor Contact
Josh Rappaport
Stern Investor Relations
212-362-1200
josh.rappaport@sternir.com

View original content:https://www.prnewswire.com/news-releases/theseus-pharmaceuticals-to-participate-in-the-cantor-future-of-oncology-virtual-symposium-301782407.html

SOURCE Theseus Pharmaceuticals

FAQ

When will Theseus Pharmaceuticals present at the Cantor Future of Oncology Virtual Symposium?

Theseus Pharmaceuticals will present on April 3, 2023, at 2:00 PM ET.

What is the focus of Theseus Pharmaceuticals?

Theseus Pharmaceuticals focuses on developing transformative targeted therapies for cancer patients.

What is Theseus' lead product candidate?

Theseus' lead product candidate is THE-630, a pan-variant KIT inhibitor for advanced gastrointestinal stromal tumors.

What types of therapies is Theseus developing?

Theseus is developing pan-variant tyrosine kinase inhibitors and selective epidermal growth factor receptor inhibitors.

Is there a live webcast for the Cantor Future of Oncology Virtual Symposium?

Yes, a live webcast will be available for registered attendees and clients of Cantor.